Dr. Lisa H. Butterfield

Lisa H. Butterfield, Ph.D. is a Consultant and Advisory Board Member in cancer immunotherapy. She was a Distinguished Scientist in Discovery-Oncology at Merck Research Labs in South San Francisco (2023-2026). Her focus at Merck was solid tumor immune-oncology, cancer vaccines and biomarkers. She was formerly the Vice President, Research and Development at the Parker Institute for Cancer Immunotherapy (PICI), and an Adjunct Professor of Microbiology and Immunology, University California San Francisco. At PICI, she supported cell therapy initiatives and clinical trial biospecimen and biomarker projects. Her academic research has been focused on cancer vaccines and cellular therapies. She was a member, then Chair of the FDA Cellular, Tissues and Gene Therapies Advisory Committee. Dr. Butterfield was previously Professor of Medicine, Surgery, Immunology and Clinical and Translational Science at the University of Pittsburgh (2003-2018) and Director of the Hillman Cancer Center Immunologic Monitoring biomarker lab as well as the cGMP Cellular Products Laboratory. She has a PhD in Biology from UCLA, followed by postdoctoral fellowships in Cellular Immunology and Cancer Gene Therapy also at UCLA. She was the first female President of the Society of Immunotherapy of Cancer (SITC, 2017-2018) and a member of the SITC Executive Committee (2015-2020). She led the Immunology Reference Lab for the ECOG-ACRIN NCI cooperative group (2006-2018) and collaborated on biomarker studies in many clinical trials. She has published >200 peer-reviewed manuscripts, reviews and book chapters, and mentored over 20 students and postdocs. She co-leads the SITC Women’s Leadership Institute and was a co-Editor of the SITC textbook “Cancer Immunotherapy: Principles and Practice” 1st and 2nd editions. Dr. Butterfield brings a wealth and depth of expertise in immunotherapy research to Arc Nouvel.